ER
ALXN

Enlightenment Research’s Alexion Pharmaceuticals ALXN Stock Holding History

Enlightenment Research’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-2,500
Closed -$382K – 231
2021
Q1 		$382K Buy
2,500
+1,200
+92% +$186K 0.46% 62
2020
Q4 		$203K Buy
+1,300
New +$167K 0.29% 81
2019
Q4 		– Sell
-2,400
Closed -$235K – 131
2019
Q3 		$235K Sell
2,400
-3,200
-57% -$361K 0.52% 70
2019
Q2 		$637K Buy
+5,600
New +$722K 0.32% 86

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Enlightenment Research's ALXN Position: Q2 2021 in Review

Enlightenment Research sold out of Alexion Pharmaceuticals (ALXN) in Q2 2021, closing a stake of 2,500 shares — an estimated $382K sold.

Enlightenment Research first reported a position in ALXN in Q2 2019 and held it in 4 quarters. The position peaked at $637K in Q2 2019. 707 funds tracked by Wall St. Rank hold ALXN as of Q2 2021.

  • Enlightenment Research reported no remaining Alexion Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Enlightenment Research sold 2,500 Alexion Pharmaceuticals shares in Q2 2021, an estimated $382K.
  • Enlightenment Research first reported a position in Alexion Pharmaceuticals in Q2 2019 and held it in 4 quarters.
  • Enlightenment Research's Alexion Pharmaceuticals position peaked at $637K in Q2 2019.
  • 707 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2021.

Based on Enlightenment Research's 13F filing for Q2 2021, filed 16 Aug 2021.